10x Genomics (TXG) Charts a Steady Path: Atera Launches as Q1 2026 Brings Helpful Margin Shifts but a Persistent Net Loss Remains

In the science of earnings, TXG’s first quarter of 2026 reads like a textbook of incremental progress. The company posted revenue of $150.8 million for the quarter, a 3% dip from the prior-year period. If you strip out a one-time $16.8 million license and royalty windfall from Q1 2025, revenue would have risen about 9% year-over-year. The narrative here isn’t a dramatic swing but a quiet re-acceleration behind new product lines and a path toward a revenue forecast for the full year that sits at $600–$625 million. The ticker, EPS discussions, and the usual earnings surprise chatter are in the air, even as the company reports a net loss and a clear emphasis on product launches and cash position.

Key numbers at a glance

Revenue: $150.8 million in Q1 2026; down 3% versus Q1 2025. Excluding the $16.8 million one-time item in Q1 2025, revenue up 9% YoY.
Gross margin: 70% for Q1 2026, up from 68% in the prior-year period.
Operating expenses: $123.2 million for Q1 2026, down 15% from $144.8 million in the prior year.
Operating loss: $17.0 million for Q1 2026; compares with a $39.3 million operating loss in the prior year period.
Net loss: $13.5 million for Q1 2026; versus a net loss of $34.4 million in the corresponding quarter last year.
Cash and equivalents / marketable securities: $539.8 million as of March 31, 2026.
Guidance: 2026 revenue forecast reaffirmed at $600–$625 million; excluding non-recurring 2025 license/royalty revenue, this implies 0%–4% growth over 2025.

In short, cost discipline and a stronger gross margin helped compress the operating loss, but the company remains unprofitable on a net basis. The equity story hinges on timing and scale of product adoption rather than a near-term pivot to profitability.

What’s driving the narrative?

Two threads are holding the storyline together. First, the launch of Atera, a new platform designed to deliver spatial whole-transcriptome analysis with single-cell sensitivity at a scale that aims to redefine how biology is measured. Management expects Atera to start shipping in the second half of 2026, a timeline that investors will scrutinize as a potential catalyst for translating R&D into revenue momentum. Second, a strategic partnership with Bioptimus to launch STELA—a multinational spatial data initiative—signals an ambition to build foundational datasets linking biology to disease outcomes. The plan here is not just product expansion; it’s a data strategy that could extend customers’ lifetime value if executed well on Xenium and later on Atera.

From a pacing perspective, the 70% gross margin and the 15% drop in operating expenses suggest the company is leveraging its scale to improve unit economics even as it continues to invest in platform development. That combination—improved margins against ongoing R&D and go-to-market investments—helps explain the narrowing operating loss despite a negative bottom line.

EPS, earnings surprises, and the road ahead

As with many growth-stage life sciences technology peers, the essential question is how soon the revenue trajectory converts into a meaningful EPS lift. The press release does not publish an EPS figure or a formal EPS consensus, so investors will be listening for those numbers on the next quarterly call. In this release, earnings surprise is not claimed; rather, the emphasis is on “ongoing progress toward the mid- to long-term financial model.” The reaffirmed revenue forecast provides a baseline for earnings expectations and will likely influence whether market participants model a near-term EPS figure above or below street expectations when the company addresses 2026 guidance in detail.

What matters most for TXG’s EPS trajectory is the pace of top-line growth, the extent to which Atera and Xenium utilization translates into higher average selling prices or volumes, and the control of operating expenses as the company scales the platform. Analysts will also weigh how much non-recurring revenue from 2025 (the patent-related item) distorts year-over-year comparisons when calculating EPS. In other words, the EPS consensus, when it arrives, will depend on how investors view the sustainability of the ex-items growth rate and the timing of Atera’s contribution to revenue.

Implications for the sector and peers

10x Genomics sits in a space where the combination of single-cell and spatial biology is increasingly treated as a platform play rather than a toolbox. The Q1 results underscore a broader industry hinge: the ability to convert breakthrough biology into recurring, scalable revenue streams. If Atera and STELA succeed in extracting durable customer value from larger spatial data initiatives, peers may face pressure to accelerate their own platform strategies, data ecosystems, and go-to-market motions. Competitors’ reactions will likely focus on the speed of product adoption, the balance between capex for instrumentation and opex for software and services, and the durability of gross margins amid ongoing investment cycles.

From a capital-allocation viewpoint, the company’s cash position provides a cushion for experimentation—exactly the kind of liquidity cushion that often sustains a long horizon investment thesis in this sector. If 2026 revenue grows toward the higher end of the guided band while gross margins stay elevated, EPS could begin to reflect operating leverage more clearly. Until then, the sector’s narrative will remain tethered to product cadence, science-driven demand, and the ability to translate R&D progress into real-world adoption across laboratories and biopharma partnerships.

Takeaways

TXG reaffirmed 2026 revenue guidance of $600–$625 million, with the growth rate dependent on the ramp of Atera and the Xenium ecosystem.
The Q1 figures show improved gross margin and lower operating expenses, resulting in a smaller operating loss, but net losses persist.
Atera’s launch timeline and Bioptimus/STELA initiatives are central to the growth narrative and the potential for a material impact on the revenue mix in H2 2026.
Key questions for investors: Will EPS momentum appear in the next quarters? What is the EPS consensus once analysts model the impact of Atera’s contributions? How durable will the revenue forecast be if 2026 excludes non-recurring items?
Peers in the sector will watch the pace at which platform revenues scale, along with the company’s ability to convert scientific breakthroughs into recurring revenue streams and positive per-share outcomes.